These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 2115586)

  • 1. Nonsteroidal antiinflammatory drug hydroxamic acids. Dual inhibitors of both cyclooxygenase and 5-lipoxygenase.
    Flynn DL; Capiris T; Cetenko WJ; Connor DT; Dyer RD; Kostlan CR; Nies DE; Schrier DJ; Sircar JC
    J Med Chem; 1990 Aug; 33(8):2070-2. PubMed ID: 2115586
    [No Abstract]   [Full Text] [Related]  

  • 2. Dibenzoxepinone hydroxylamines and hydroxamic acids: dual inhibitors of cyclooxygenase and 5-lipoxygenase with potent topical antiinflammatory activity.
    Hamer RR; Tegeler JJ; Kurtz ES; Allen RC; Bailey SC; Elliott ME; Hellyer L; Helsley GC; Przekop P; Freed BS; White J; Martin LL
    J Med Chem; 1996 Jan; 39(1):246-52. PubMed ID: 8568814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Meclofenamate sodium is an inhibitor of both the 5-lipoxygenase and cyclooxygenase pathways of the arachidonic acid cascade in vitro.
    Boctor AM; Eickholt M; Pugsley TA
    Prostaglandins Leukot Med; 1986 Aug; 23(2-3):229-38. PubMed ID: 3020588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The in vivo antiinflammatory effects of (E)-2,6-bis(1,1-dimethyl-ethyl)-4-[2-(5-methyl-1H-pyrazol-3-yl)ethenyl ] phenol (PD 127443) a novel dual inhibitor of 5-lipoxygenase and cyclooxygenase.
    Schrier DJ; Adamchak MA; Boctor AM; Kostlan CR; Flynn DL; Jordan JH; Lesch ME; Okonkwo GC
    Agents Actions; 1989 Jun; 27(3-4):391-4. PubMed ID: 2552768
    [No Abstract]   [Full Text] [Related]  

  • 5. Ethanesulfohydroxamic acid ester prodrugs of nonsteroidal anti-inflammatory drugs (NSAIDs): synthesis, nitric oxide and nitroxyl release, cyclooxygenase inhibition, anti-inflammatory, and ulcerogenicity index studies.
    Huang Z; Velázquez CA; Abdellatif KR; Chowdhury MA; Reisz JA; DuMond JF; King SB; Knaus EE
    J Med Chem; 2011 Mar; 54(5):1356-64. PubMed ID: 21280601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acetohydroxamic acids as potent, selective, orally active 5-lipoxygenase inhibitors.
    Jackson WP; Islip PJ; Kneen G; Pugh A; Wates PJ
    J Med Chem; 1988 Mar; 31(3):499-500. PubMed ID: 3346867
    [No Abstract]   [Full Text] [Related]  

  • 7. Hydroxamic acid inhibitors of 5-lipoxygenase.
    Summers JB; Mazdiyasni H; Holms JH; Ratajczyk JD; Dyer RD; Carter GW
    J Med Chem; 1987 Mar; 30(3):574-80. PubMed ID: 3820229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of 5-lipoxygenase inhibitors and leukotriene antagonists on the development of gastric lesions induced by nonsteroidal antiinflammatory drugs in mice.
    Rainsford KD
    Agents Actions; 1987 Aug; 21(3-4):316-9. PubMed ID: 3687587
    [No Abstract]   [Full Text] [Related]  

  • 9. Release of PAF-acether and eicosanoids from guinea-pig alveolar macrophages by FMLP: effect of cyclo-oxygenase and lipoxygenase inhibition.
    Fitzgerald MF; Parente L; Whittle BJ
    Eur J Pharmacol; 1989 May; 164(3):539-46. PubMed ID: 2548873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FPL 62064, a topically active 5-lipoxygenase/cyclooxygenase inhibitor.
    Blackham A; Griffiths RJ; Hallam C; Mann J; Mitchell PD; Norris AA; Simpson WT
    Agents Actions; 1990 Jun; 30(3-4):432-42. PubMed ID: 2117338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo characterization of hydroxamic acid inhibitors of 5-lipoxygenase.
    Summers JB; Gunn BP; Mazdiyasni H; Goetze AM; Young PR; Bouska JB; Dyer RD; Brooks DW; Carter GW
    J Med Chem; 1987 Nov; 30(11):2121-6. PubMed ID: 3669019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-652,343: a novel dual 5-lipoxygenase/cyclooxygenase inhibitor.
    Tischler A; Bailey P; Dallob A; Witzel B; Durette P; Rupprecht K; Allison D; Dougherty H; Humes J; Ham E
    Adv Prostaglandin Thromboxane Leukot Res; 1986; 16():63-6. PubMed ID: 2949565
    [No Abstract]   [Full Text] [Related]  

  • 13. 1,2-Dihydro-1-oxopyrrolo[3,2,1-kl]phenothiazine-2-carboxamides and congeners, dual cyclooxygenase/5-lipoxygenase inhibitors with antiinflammatory activity.
    Mylari BL; Carty TJ; Moore PF; Zembrowski WJ
    J Med Chem; 1990 Jul; 33(7):2019-24. PubMed ID: 2113951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of a novel series of selective inhibitors of arachidonate 5-lipoxygenase on anaphylactic and inflammatory responses.
    Bhattacherjee P; Boughton-Smith NK; Follenfant RL; Garland LG; Higgs GA; Hodson HF; Islip PJ; Jackson WP; Moncada S; Payne AN
    Ann N Y Acad Sci; 1988; 524():307-20. PubMed ID: 2837965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxamic acid inhibitors of 5-lipoxygenase: quantitative structure-activity relationships.
    Summers JB; Kim KH; Mazdiyasni H; Holms JH; Ratajczyk JD; Stewart AO; Dyer RD; Carter GW
    J Med Chem; 1990 Mar; 33(3):992-8. PubMed ID: 2308149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological properties of a new anti-inflammatory compound, alpha-(3,5-di-tert-butyl-4-hydroxybenzylidene)-gamma-butyrolacto ne (KME-4), and its inhibitory effects on prostaglandin synthetase and 5-lipoxygenase.
    Hidaka T; Hosoe K; Ariki Y; Takeo K; Yamashita T; Katsumi I; Kondo H; Yamashita K; Watanabe K
    Jpn J Pharmacol; 1984 Sep; 36(1):77-85. PubMed ID: 6438380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonsteroidal anti-inflammatory drugs as scaffolds for the design of 5-lipoxygenase inhibitors.
    Kolasa T; Brooks CD; Rodriques KE; Summers JB; Dellaria JF; Hulkower KI; Bouska J; Bell RL; Carter GW
    J Med Chem; 1997 Feb; 40(5):819-24. PubMed ID: 9057869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of the inhibition of rat gastric mucosal 5-lipoxygenase by novel acetohydroxamic acids to prevent ethanol-induced damage.
    Boughton-Smith NK; Whittle BJ
    Br J Pharmacol; 1988 Sep; 95(1):155-62. PubMed ID: 3146394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selectivity of neutrophil 5-lipoxygenase and cyclo-oxygenase inhibition by an anti-inflammatory flavonoid glycoside and related aglycone flavonoids.
    Moroney MA; Alcaraz MJ; Forder RA; Carey F; Hoult JR
    J Pharm Pharmacol; 1988 Nov; 40(11):787-92. PubMed ID: 2907559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salicylates inhibit PAF-acether-induced rat paw oedema when cyclooxygenase inhibitors are ineffective.
    Cordeiro RS; Silva PM; Martins MA; Vargaftig BB
    Prostaglandins; 1986 Nov; 32(5):719-27. PubMed ID: 3103172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.